ACVR2B and cancer: The pharmacological blockade of myostatin/activin pathway via the administration of an anti-myostatin monoclonal antibody that inhibit the binding of myostatin to its receptor ActRIIB/ACVR2B was found to be the most effective treatment for muscle wasting in cancer cachetic patients (Lach-Trifilieff et al. 2014).